{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:44:17Z","timestamp":1790685857813,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009730","name":"Stand Up To Cancer","doi-asserted-by":"publisher","award":["2.0"],"award-info":[{"award-number":["2.0"]}],"id":[{"id":"10.13039\/100009730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K12HD055887"],"award-info":[{"award-number":["K12HD055887"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA154460-01"],"award-info":[{"award-number":["R01 CA154460-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01 CA176067-01A1"],"award-info":[{"award-number":["U01 CA176067-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006696","name":"Fondazione Guido Berlucchi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006696","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014487","name":"Clovis Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014487","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.ygyno.2020.07.016","type":"journal-article","created":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T18:00:29Z","timestamp":1595354429000},"page":"17-22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"title":["Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study"],"prefix":"10.1016","volume":"159","author":[{"given":"Britt K.","family":"Erickson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Najjar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shari","family":"Damast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Blakaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Tymon-Rosario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Shahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Santin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Dolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Cimino-Mathews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Buza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Stuart","family":"Ferriss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Khalifa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda N.","family":"Fader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ygyno.2020.07.016_bb0005","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/sj.bjc.6603012","article-title":"Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers","volume":"94","author":"Hamilton","year":"2006","journal-title":"Br. J. Cancer"},{"issue":"10","key":"10.1016\/j.ygyno.2020.07.016_bb0010","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1002\/cncr.24247","article-title":"Platinum\/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma","volume":"115","author":"Fader","year":"2009","journal-title":"Cancer."},{"issue":"3","key":"10.1016\/j.ygyno.2020.07.016_bb0015","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ygyno.2008.11.016","article-title":"Stage II uterine papillary serous carcinoma: carboplatin\/paclitaxel chemotherapy improves recurrence and survival outcomes","volume":"112","author":"Fader","year":"2009","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2020.07.016_bb0020","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ygyno.2007.01.041","article-title":"Outcomes in surgical stage I uterine papillary serous carcinoma","volume":"105","author":"Havrilesky","year":"2007","journal-title":"Gynecol. Oncol."},{"issue":"12","key":"10.1016\/j.ygyno.2020.07.016_bb0025","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1002\/ijc.26292","article-title":"Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes--a systematic review","volume":"130","author":"Chua","year":"2012","journal-title":"Int. J. Cancer"},{"issue":"7","key":"10.1016\/j.ygyno.2020.07.016_bb0030","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1245\/s10434-011-1554-1","article-title":"Her-2\/neu gene amplification in esophageal adenocarcinoma and its influence on survival","volume":"18","author":"Thompson","year":"2011","journal-title":"Ann. Surg. Oncol."},{"issue":"11","key":"10.1016\/j.ygyno.2020.07.016_bb0035","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","article-title":"Human epidermal growth factor receptor 2 testing in breast Cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update","volume":"142","author":"Wolff","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"7","key":"10.1016\/j.ygyno.2020.07.016_bb0040","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/hed.20574","article-title":"Prognostic impact of HER-2\/neu expression on squamous head and neck carcinomas","volume":"29","author":"Cavalot","year":"2007","journal-title":"Head Neck"},{"issue":"15","key":"10.1016\/j.ygyno.2020.07.016_bb0045","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1200\/JCO.2004.11.154","article-title":"Her-2\/neu overexpression and amplification in uterine papillary serous carcinoma","volume":"22","author":"Slomovitz","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.ygyno.2020.07.016_bb0050","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/cncr.21308","article-title":"Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma","volume":"104","author":"Santin","year":"2005","journal-title":"Cancer."},{"issue":"15","key":"10.1016\/j.ygyno.2020.07.016_bb0055","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1200\/JCO.2005.03.4827","article-title":"HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients","volume":"24","author":"Morrison","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2020.07.016_bb0060","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/GCO.0000000000000599","article-title":"Targeting human epidermal growth factor receptor 2 (HER2) in gynecologic malignancies","volume":"32","author":"Erickson","year":"2020","journal-title":"Curr. Opin. Obstet. Gynecol."},{"issue":"20","key":"10.1016\/j.ygyno.2020.07.016_bb0065","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","article-title":"Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-Trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2\/neu","volume":"36","author":"Fader","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2020.07.016_bb0070","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5858\/2007-131-18-ASOCCO","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer","volume":"131","author":"Wolff","year":"2007","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"12","key":"10.1016\/j.ygyno.2020.07.016_bb0075","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/modpathol.2013.113","article-title":"Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice","volume":"26","author":"Buza","year":"2013","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ygyno.2020.07.016_bb0080","doi-asserted-by":"crossref","unstructured":"Buza N, Roque DM, Santin AD. HER2\/neu in endometrial Cancer: a promising therapeutic target with diagnostic challenges. Arch. Pathol. Lab. Med. 2014 Mar;138(3):343\u201350. PubMed PMID: 24576030.","DOI":"10.5858\/arpa.2012-0416-RA"},{"issue":"21","key":"10.1016\/j.ygyno.2020.07.016_bb0085","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1038\/sj.onc.1206394","article-title":"HER2\/PI-3K\/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells","volume":"22","author":"Knuefermann","year":"2003","journal-title":"Oncogene."},{"issue":"9","key":"10.1016\/j.ygyno.2020.07.016_bb0090","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1634\/theoncologist.2017-0379","article-title":"Genomic profiling of HER2-positive gastric Cancer: PI3K\/Akt\/mTOR Pathway as predictor of outcomes in HER2-positive advanced gastric Cancer treated with Trastuzumab","volume":"23","author":"Diaz-Serrano","year":"2018","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.ygyno.2020.07.016_bb0095","first-page":"1271","article-title":"Overexpression of HER-2\/neu in uterine serous papillary cancer","volume":"8","author":"Santin","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2020.07.016_bb0100","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.gore.2016.12.003","article-title":"Regression of metastatic, radiation\/chemotherapy-resistant uterine serous carcinoma overexpressing HER2\/neu with trastuzumab emtansine (TDM-1)","volume":"19","author":"Santin","year":"2017","journal-title":"Gynecol. Oncol. Rep."},{"issue":"8","key":"10.1016\/j.ygyno.2020.07.016_bb0105","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1158\/1535-7163.MCT-16-0163","article-title":"SYD985, a novel Duocarmycin-based HER2-targeting antibody-drug conjugate, shows antitumor activity in uterine serous carcinoma with HER2\/Neu expression","volume":"15","author":"Black","year":"2016","journal-title":"Mol. Cancer Ther."},{"issue":"5","key":"10.1016\/j.ygyno.2020.07.016_bb0110","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1002\/cam4.274","article-title":"T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo","volume":"3","author":"English","year":"2014","journal-title":"Cancer medicine."},{"issue":"1","key":"10.1016\/j.ygyno.2020.07.016_bb0115","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/sj.bjc.6605448","article-title":"In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma","volume":"102","author":"El-Sahwi","year":"2010","journal-title":"Br. J. Cancer"},{"issue":"9","key":"10.1016\/j.ygyno.2020.07.016_bb0120","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1038\/bjc.2014.519","article-title":"Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo","volume":"111","author":"Schwab","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2020.07.016_bb0125","doi-asserted-by":"crossref","unstructured":"Schwab CL, English DP, Roque DM, Bellone S, Lopez S, Cocco E, et al. Neratinib shows efficacy in the treatment of HER2\/neu amplified uterine serous carcinoma in vitro and in vivo. Gynecol. Oncol. 2014 Oct;135(1):142\u20138. PubMed PMID: 25124161.","DOI":"10.1016\/j.ygyno.2014.08.006"},{"issue":"2","key":"10.1016\/j.ygyno.2020.07.016_bb0130","doi-asserted-by":"crossref","first-page":"170","DOI":"10.6004\/jnccn.2018.0006","article-title":"Uterine neoplasms, version 1.2018, NCCN clinical practice guidelines in oncology","volume":"16","author":"Koh","year":"2018","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"12","key":"10.1016\/j.ygyno.2020.07.016_bb0135","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/gcc.22113","article-title":"Marked heterogeneity of HER2\/NEU gene amplification in endometrial serous carcinoma","volume":"52","author":"Buza","year":"2013","journal-title":"Genes Chromosom. Cancer"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082582032391X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082582032391X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T09:28:44Z","timestamp":1778664524000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082582032391X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S009082582032391X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.07.016","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.07.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}